Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. filed an 8-K on July 17, 2026, continuing its SEC reporting obligations as the operating company that emerged from a de-SPAC transaction with Amplitude Healthcare Acquisition Corporation, which traded on Nasdaq under the ticker AMHC. The blank-check vehicle, sponsored by Amplitude Healthcare-affiliated management, completed its initial public offering in 2021 and targeted the healthcare and life sciences sector. The combined company, Jasper Therapeutics, focuses on clinical-stage development of therapies grounded in hematopoietic stem cell biology for serious hematologic and immune conditions. Sign up at SpacDesk for full data on AMHC filings, sponsor details, and comprehensive SPAC deal analytics.